Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,892

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The Parkinson Progression Marker Initiative (PPMI)

Open access
Marek, Kenneth, Jennings, Danna, Lasch, Shirley, Siderowf, Andrew, Tanner, Caroline, Simuni, Tanya, Coffey, Chris, Kieburtz, Karl, Flagg, Emily, Chowdhury, Sohini, Poewe, Werner, Mollenhauer, Brit, Klinik, Paracelsus-Elena, Sherer, Todd, Frasier, Mark, Meunier, Claire, Rudolph, Alice, Casaceli, Cindy, Seibyl, John, Mendick, Susan, Schuff, Norbert, Zhang, Ying, Toga, Arthur, Crawford, Karen, Ansbach, Alison, De Blasio, Pasquale, Piovella, Michele, Trojanowski, John, Shaw, Les, Singleton, Andrew, Hawkins, Keith, Eberling, Jamie, Brooks, Deborah, Russell, David, Leary, Laura, Factor, Stewart, Sommerfeld, Barbara, Hogarth, Penelope, Pighetti, Emily, Williams, Karen, Standaert, David, Guthrie, Stephanie, Hauser, Robert, Delgado, Holly, Jankovic, Joseph, Hunter, Christine, Stern, Matthew, Tran, Baochan, Leverenz, Jim, Baca, Marne, Frank, Sam, Thomas, Cathi-Ann, Richard, Irene, Deeley, Cheryl, Rees, Linda, Sprenger, Fabienne, Lang, Elisabeth, Shill, Holly, Obradov, Sanja, Fernandez, Hubert, Winters, Adrienna, Berg, Daniela, Gauss, Katharina, Galasko, Douglas, Fontaine, Deborah, Mari, Zoltan, Gerstenhaber, Melissa, Brooks, David, Malloy, Sophie, Barone, Paolo, Longo, Katia, Comery, Tom, Ravina, Bernard, Grachev, Igor, Gallagher, Kim, Collins, Michelle, Widnell, Katherine L., Ostrowizki, Suzanne, Fontoura, Paulo, Ho, Tony, Luthman, Johan, Brug, Marcel van der, Reith, Alastair D., Taylor, Peggy·2011·Progress in Neurobiology
DOI 10.1016/j.pneurobio.2011.09.005
Open this paper in CoChat — free account

Abstract

The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multicenter study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials. The PPMI cohort will comprise 400 recently diagnosed PD and 200 healthy subjects followed longitudinally for clinical, imaging and biospecimen biomarker assessment using standardized data acquisition protocols at twenty-one clinical sites. All study data will be integrated in the PPMI study database and will be rapidly and publically available through the PPMI web site- www.ppmi-info.org. Biological samples including longitudinal collection of blood, cerebrospinal fluid (CSF) and urine will be available to scientists by application to an independent PPMI biospecimen review committee also through the PPMI web site. PPMI will rely on a partnership of government, PD foundations, industry and academics working cooperatively. This approach is crucial to enhance the potential for success of this ambitious strategy to develop PD progression biomarkers that will accelerate research in disease modifying therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pneurobio.2011.09.005

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 38

  1. Aisen, 2010, Clinical core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans, Alzheimers Dement., 6, 239, 10.1016/j.jalz.2010.03.006 · DOI · Paper page
  2. Beyer, 2007, Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies, Neurology, 69, 747, 10.1212/01.wnl.0000269666.62598.1c · DOI · Paper page
  3. Braak, 2008, Invited Article: nervous system pathology in sporadic Parkinson disease, Neurology, 70, 1916, 10.1212/01.wnl.0000312279.49272.9f · DOI · Paper page
  4. Colosimo, 2010, Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations, Mov. Disord., 25, 1131, 10.1002/mds.23072 · DOI
  5. Eckert, 2007, Assessment of the progression of Parkinson's disease: a metabolic network approach, Lancet Neurol., 6, 926, 10.1016/S1474-4422(07)70245-4 · DOI · Paper page
  6. El-Agnaf, 2006, Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease, FASEB J., 20, 419, 10.1096/fj.03-1449com · DOI · Paper page
  7. Fearnley, 1990, Striatonigral degeneration: a clinico-pathological study, Brain, 113, 1823, 10.1093/brain/113.6.1823 · DOI · Paper page
  8. Gerlach, 2008, Early detection of Parkinson's disease: unmet needs, Neurodegener. Dis., 5, 137, 10.1159/000113683 · DOI
  9. Jankovic, 1990, Lower body (vascular) parkinsonism, Arch. Neurol., 47, 728, 10.1001/archneur.1990.00530070014003 · doi:10.1001/archneur.1990.00530070014003
  10. Klein, 2007, Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder, Neurology, 69, 2093, 10.1212/01.wnl.0000271880.27321.a7 · DOI · Paper page
  11. Langston, 2006, The Parkinson's complex: parkinsonism is just the tip of the iceberg, Ann. Neurol., 59, 591, 10.1002/ana.20834 · DOI · Paper page
  12. Maetzler, 2009, Progression of Parkinson's disease in the clinical phase: potential markers, Lancet Neurol., 8, 1158, 10.1016/S1474-4422(09)70291-1 · DOI · Paper page
  13. Marek, 2009, Can we image premotor Parkinson disease?, Neurology, 72, S21, 10.1212/WNL.0b013e318198df97 · DOI
  14. Marek, 2008, Biomarkers for Parkinson's disease: tools to assess Parkinson's disease onset and progression, Ann. Neurol., 64, S111
  15. Mollenhauer, 2009, Neurochemical biomarkers in the differential diagnosis of movement disorders, Mov. Disord., 24, 1411, 10.1002/mds.22510 · DOI
  16. Montine, 2010, CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment, Mov. Disord., 25, 2682, 10.1002/mds.23287 · DOI · Paper page
  17. Olanow, 2006, TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial, Lancet Neurol., 5, 1013, 10.1016/S1474-4422(06)70602-0 · DOI · Paper page
  18. Olanow, 2008, Why have we failed to achieve neuroprotection in Parkinson's disease?, Ann. Neurol., 64, S101
  19. Olanow, 2009, A double-blind, delayed-start trial of rasagiline in Parkinson's disease, N. Engl. J. Med., 361, 1268, 10.1056/NEJMoa0809335 · DOI · Paper page
  20. 1993, Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease, N. Engl. J. Med., 328, 176, 10.1056/NEJM199301213280305 · DOI · Paper page
  21. 2004, Levodopa and the progression of Parkinson disease, NEMJ, 351, 18
  22. 2007, Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease, Neurology, 69, 1480, 10.1212/01.wnl.0000277648.63931.c0 · DOI · Paper page
  23. Peran, 2010, Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature, Brain, 133, 3423, 10.1093/brain/awq212 · DOI · Paper page
  24. Ravina, 2005, The role of radiotracer imaging in Parkinson disease, Neurology, 64, 208, 10.1212/01.WNL.0000149403.14458.7F · DOI · Paper page
  25. Ravina, 2009, A longitudinal program for biomarker development in Parkinson's disease: a feasibility study, Mov. Disord., 24, 2081, 10.1002/mds.22690 · DOI
  26. Schapira, 2004, Disease modification in Parkinson's disease, Lancet Neurol., 3, 362, 10.1016/S1474-4422(04)00769-0 · DOI
  27. Schapira, 2010, Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study, Mov. Disord., 25, 1627, 10.1002/mds.23143 · DOI
  28. Scherzer, 2007, Molecular markers of early Parkinson's disease based on gene expression in blood, Proc. Natl. Acad. Sci. U.S.A., 104, 955, 10.1073/pnas.0610204104 · DOI · Paper page
  29. Schmidt, 2010, The Alzheimer's Disease Neuroimaging Initiative: perspectives of the Industry Scientific Advisory Board, Alzheimers Dement., 6, 286, 10.1016/j.jalz.2010.03.010 · DOI
  30. Seibyl, 2010, The role of the core imaging laboratory in multicenter trials, Semin. Nucl. Med., 40, 338, 10.1053/j.semnuclmed.2010.03.002 · DOI
  31. Shi, 2009, Biomarker discovery in neurodegenerative diseases: a proteomic approach, Neurobiol. Dis., 35, 157, 10.1016/j.nbd.2008.09.004 · DOI
  32. Siderowf, 2010, CSF amyloid β1–42 predicts cognitive decline in Parkinson disease, Neurology, 75, 1055, 10.1212/WNL.0b013e3181f39a78 · DOI · Paper page
  33. The Lancet, 2010, Biomarker promise for Parkinson's disease, Lancet Neurol., 9, 1139, 10.1016/S1474-4422(10)70284-2 · doi:10.1016/s1474-4422(10)70284-2
  34. Trojanowski, 2010, Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects, Alzheimers Dement., 6, 230, 10.1016/j.jalz.2010.03.008 · DOI · Paper page
  35. Vaillancourt, 2009, High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease, Neurology, 72, 1378, 10.1212/01.wnl.0000340982.01727.6e · DOI · Paper page
  36. Vornov, 2006, GPI 1485, a neuroimmunophilin ligand, fails to alter disease progression in mild to moderate Parkinson's disease, Mov. Disord.
  37. Weiner, 2010, The Alzheimer's Disease Neuroimaging Initiative: progress report and future plans, Alzheimers Dement., 6, 202 e7, 10.1016/j.jalz.2010.03.007 · DOI · Paper page
  38. Whone, 2003, Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study, Ann. Neurol., 54, 93, 10.1002/ana.10609 · DOI · Paper page

Cited by

See all 1,892

Metadata

Authors
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., Poewe, W., Mollenhauer, B., Klinik, P.-E., Sherer, T., Frasier, M., Meunier, C., Rudolph, A., Casaceli, C., Seibyl, J., Mendick, S., Schuff, N., Zhang, Y., Toga, A., Crawford, K., Ansbach, A., De Blasio, P., Piovella, M., Trojanowski, J., Shaw, L., Singleton, A., Hawkins, K., Eberling, J., Brooks, D., Russell, D., Leary, L., Factor, S., Sommerfeld, B., Hogarth, P., Pighetti, E., Williams, K., Standaert, D., Guthrie, S., Hauser, R., Delgado, H., Jankovic, J., Hunter, C., Stern, M., Tran, B., Leverenz, J., Baca, M., Frank, S., Thomas, C.-A., Richard, I., Deeley, C., Rees, L., Sprenger, F., Lang, E., Shill, H., Obradov, S., Fernandez, H., Winters, A., Berg, D., Gauss, K., Galasko, D., Fontaine, D., Mari, Z., Gerstenhaber, M., Brooks, D., Malloy, S., Barone, P., Longo, K., Comery, T., Ravina, B., Grachev, I., Gallagher, K., Collins, M., Widnell, K. L., Ostrowizki, S., Fontoura, P., Ho, T., Luthman, J., Brug, M. V. D., Reith, A. D., & Taylor, P.
Venue
Progress in Neurobiology
Publisher
Elsevier BV
Published
2011-12
Volume
95
Issue
4
Pages
629-635
ISSN
0301-0082 (ISSN-L)
DOI
10.1016/j.pneurobio.2011.09.005
OpenAlex
W1988494453
Cited by
1,892
References
4
FWCI
15.73
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Parkinson Progression Marker Initiative (PPMI). https://app.cochat.ai/papers/10.1016/j.pneurobio.2011.09.005
The paper
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., Poewe, W., Mollenhauer, B., Klinik, P.-E., Sherer, T., Frasier, M., Meunier, C., Rudolph, A., Casaceli, C., Seibyl, J., . . . Taylor, P. (2011). The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2011.09.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.